Yanfei Sun

Jinan, 250012, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

ECE1c promotes glioblastoma invasion via the ROCK2-MYH10 axis and interaction with ACTB.

ECE1c promotes glioblastoma invasion via the ROCK2-MYH10 axis and interaction with ACTB.

Journal: American journal of translational research

Published: January 21, 2026

Machine learning models diagnose oral squamous cell carcinoma based on cross-cohort oral microbial signatures.

Machine learning models diagnose oral squamous cell carcinoma based on cross-cohort oral microbial signatures.

Journal: Frontiers in microbiology

Published: August 25, 2025

Dual role of WNT10A in promoting the malignancy of glioblastoma and remodeling the tumor microenvironment.

Dual role of WNT10A in promoting the malignancy of glioblastoma and remodeling the tumor microenvironment.

Journal: Neuro-oncology

Published: March 18, 2025

The construction of an inflammation classification model for HDPCs applied in guiding pulpotomy based on single-cell Raman spectroscopy.

The construction of an inflammation classification model for HDPCs applied in guiding pulpotomy based on single-cell Raman spectroscopy.

Journal: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Published: March 30, 2024

Polyunsaturated fatty acid-binding protein FABP7, an attractive metabolic target for inhibition of glioblastoma stem cells.

Polyunsaturated fatty acid-binding protein FABP7, an attractive metabolic target for inhibition of glioblastoma stem cells.

Journal: Neuro-oncology

Published: January 20, 2024

Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma.

Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma.

Journal: Scientific reports

Published: January 17, 2024

Metabolic modulation of histone acetylation mediated by HMGCL activates the FOXM1/β-catenin pathway in glioblastoma.

Metabolic modulation of histone acetylation mediated by HMGCL activates the FOXM1/β-catenin pathway in glioblastoma.

Journal: Neuro-oncology

Published: December 09, 2023

ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma.

ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma.

Journal: PloS one

Published: October 27, 2023

The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions.

The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 08, 2023

Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles' heel for glioblastoma.

Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles' heel for glioblastoma.

Journal: Neuro-oncology

Published: August 25, 2023

Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM).

Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM).

Journal: Frontiers in oncology

Published: July 08, 2023

Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma.

Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma.

Journal: Journal of translational medicine

Published: May 04, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026